Malaria continues to be a major health challenge in the world. *Plasmodium falciparum* causes the most virulent form of human malaria. In 2012, it killed over 600,000 children, largely in sub-Saharan Africa (1). The asexual-blood-stage parasite infects erythrocytes and is responsible for all of the symptoms and pathology associated with disease. Uncomplicated malaria consists of cycles of high fever and chills. Severe malaria includes additional pathologies, including anemia, respiratory distress, lactic acidosis, and cerebral malaria (2).

Severe malaria greatly increases the risk of death. The major pathophysiologic state is severe malarial anemia (SMA). SMA is a complex disease, associated with partial immunity and results from the loss of both uninfected and infected erythrocytes, along with a concomitant block in erythropoiesis (2–4). Rapid hematologic reductions of 20 to 50% are commonly observed and must be rescued by transfusion (which can carry a risk of HIV acquisition). The causes and risk factors of SMA remain poorly understood. Recent studies suggest that SMA is linked to parasite biomass sequestered in organs. This led us to investigate whether immune mechanisms that clear parasites in organs may trigger changes leading to anemia. Here, we use an outbred-rat model where increasing parasite removal in the spleen escalated uninfected-erythrocyte removal. Splenic parasite clearance was associated with activated CD8⁺ T cells, immunodepletion of which prevented parasite clearance. CD8⁺ T cell repletion and concomitant reduction of the parasite load was associated with exacerbated (40 to 60%) hemoglobin loss and changes in properties of uninfected erythrocytes. Together, these data suggest that CD8⁺ T cell-dependent parasite clearance causes erythrocyte removal in the spleen and thus anemia.

In children infected with the human malaria parasite *Plasmodium falciparum*, elevation of parasite biomass (not the number of circulating parasites) increased the odds ratio for SMA by 3.5-fold (95% confidence intervals [CI₉₅%], 1.8- to 7.5-fold). CD8⁺ T cell repletion and concomitant reduction of the parasite load was associated with exacerbated (40 to 60%) hemoglobin loss and changes in properties of uninfected erythrocytes. Together, these data suggest that CD8⁺ T cell-dependent parasite clearance may predispose individuals to uninfected-erythrocyte loss and SMA, thus informing severe disease diagnosis and strategies for vaccine development.

**IMPORTANCE** Malaria is a major global health problem. Severe malaria anemia (SMA) is a complex disease associated with partial immunity. Rapid hemoglobin reductions of 20 to 50% are commonly observed and must be rescued by transfusion (which can carry a risk of HIV acquisition). The causes and risk factors of SMA remain poorly understood. Recent studies suggest that SMA is linked to parasite biomass sequestered in organs. This led us to investigate whether immune mechanisms that clear parasites in organs trigger anemia. In rats, erythropoiesis is largely restricted to the bone marrow, and critical aspects of the spleen expected to be important in anemia are similar to those in humans. Therefore, using a rat model, we show that severe anemia is caused through CD8⁺ T cell-dependent parasite clearance and erythrocyte removal in the spleen. CD8 activation may also be a new risk factor for SMA in African children.
globin reductions of 20 to 50% are commonly observed (5) and must be rescued by transfusion (which can carry a risk of other infections). However, the cause of this reduction and whether it also inexplicably influences dyserythropoiesis remain poorly understood. SMA in human populations is not proportional to circulating parasitemia, and recent studies suggest that it is linked to total parasite biomass sequestered in organs (6, 7). This led us to query whether immune mechanisms that kill parasites in organs may trigger anemia.

Mechanistic investigation can be greatly facilitated by relevant animal models and organ systems with physiological correspondence to human systems. Malarial anemia has previously been investigated in several mice and rat models (8–11). Murine models are attractive due to the availability of genetics and related tools. However, one drawback is that erythropoiesis, which in humans is in the bone marrow, is anomalously active in the mouse spleen (especially in response to a stress like anemia) (9, 12). This profoundly influences the organizational and functional components of an organ expected to be important in erythrocyte removal, a major mechanism of anemia (9). In contrast, in rats, erythropoiesis is largely restricted to the bone marrow, and critical aspects of the spleen red pulp architecture are similar to those of humans (13, 14). Hence, the pathophysiology of human splenic disease is likely to be better mimicked and measured in rats, whose larger size also facilitates monitoring anemia. Here, we have utilized the Wistar rat model, where malarial anemia is due to erythrocyte removal rather than dyserythropoiesis (8). We elucidate splenic mechanisms that exacerbate anemia by erythrocyte removal (up to ~50 to 60% hemoglobin reduction). We further extend these findings to patient studies and thus identify new risk factors for SMA in African children.

RESULTS

Comparative analysis of spleens and livers from aged Wistar rats infected with Plasmodium berghei ANKA reveals that the spleen shows mass expansion associated with anemia and the major parasite burden.

Rats infected with wild-type P. berghei ANKA displayed low peripheral parasitemia (3%) that peaked at day 8 postinfection (p.i.) (Fig. 1A). At day 10, peripheral parasitemia and the hematocrit declined. By days 12 to 14, parasites were completely eliminated, with an ~20% reduction in the hematocrit (range, 16 to 40%), suggesting simultaneous clearance of both infected and uninfected erythrocytes (the variation in hematocrit reduction is characteristic of an outbred model [8, 10]). The subsequent robust increase of reticulocytes (Fig. 1B) confirmed that erythrocyte reduction (or anemia) was not due to a block in erythropoiesis. Rather, it was by removal of uninfected erythrocytes (since the hematocrit declined 20% at 3% parasitemia). After recovery from anemia (days 24 to 28), the animals were cured and immune to subsequent parasite challenge (8, 10).

Since this is a model of malarial anemia, the spleen and the liver are expected to be the major affected organs. Notably, there was, on average, a >5-fold increase in spleen mass but no increase in liver mass by day 10 (Fig. 1C). Elevation of mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH), highly characteristic of stress erythropoiesis, in the bone marrow (as in humans) was also noted (Fig. 1D and E), suggesting that the splenic expansion shown in Fig. 1C was not linked to increased splenic erythropoiesis (as in murine systems) but that it may play a major role in the removal of infected and uninfected erythrocytes.

Anemia has been linked to total parasite biomass in organs in human falciparum malaria (7). Quantitative PCR (qPCR) revealed that at day 8 (of peak infection), the rat spleen was the major site of P. berghei burden, containing over 70% of the parasites (Fig. 1F, upper panel). By day 10, there was a 34-fold reduction in the number of parasites in the spleen (to levels lower than in the liver, which remained unchanged), and the dynamics of splenic clearance was the same for wild-type and mutant parasites (10). Pathological analyses of lung, kidney, and brain failed to reveal significant parasite material compared to that in the spleen or even the liver (see Fig. S1 in the supplemental material). The lung showed small mass fluctuations, but they were largely reductions, and their dynamics were not coincident with peak infection, numbers of detectable parasites, or anemia (see Table S1). Together, these data suggested that spleen was the major site of parasite burden. Moreover, the timing of parasite elimination was also that of erythrocyte clearance and anemia.

We further investigated a P. berghei ANKA mutant with a deletion of msp7, a gene implicated in blood cell invasion and thus likely to influence total parasite load and anemia (10). At day 8, there was no difference in parasite loads in the liver, but in the spleen, the Δmsp7 strain’s peak load was 3-fold lower than that of its wild-type counterpart (Fig. 1F). Δmsp7 strain clearance was coincident with a 14-fold reduction in spleen parasites at day 10 and a 10% reduction of uninfected erythrocytes at day 12 (Fig. 1F). This comparative analysis of the Δmsp7 and wild-type parasites suggested that increasing fold parasite clearance in the spleen escalated uninfected-erythrocyte removal and thus anemia.

Expansion of splenic CD8+ T cells, in wild type relative to Δmsp7 infection. To understand in an unbiased way splenic processes that underlie increased clearance of parasite load (rather than overall infection per se), we examined differences in host response to wild-type parasites relative to Δmsp7 mutant parasites. To do this, we undertook whole-genome microarray expression analyses of wild-type- relative to mutant-infected spleens at day 10 (uninfected animals were also included as controls) (Fig. S2A). Three hundred seventy-seven genes showed significant changes in expression (>1.5-fold change, P = 0.005) (Table S2A). In the top network (Fig. 2A), 7 (of the top 20) genes were for granymes (including granzyme B), suggesting involvement of CD8+ T cells or NK cells.

Flow cytometry analyses confirmed that P. berghei infection induced infiltration of B cells, NK cells, and CD3+ T cells (both CD8+ and CD4+ T cells) in the spleen (see the combined information of Fig. 2B and C and S2B and C). NK cell counts remained low, with no difference seen between wild-type- and mutant-infected spleens (Fig. 2B), which also showed no significant differences in B cell counts (Fig. S2B). Wild-type-associated elevation was seen in CD3+ T cells, with a 1.5-fold increase in CD8+ T cells on day 10 in wild-type- compared to Δmsp7 mutant-infected cells (Fig. 2C).

Quantitative immunohistochemical (IHC) analyses of spleen zones revealed that compared to Δmsp7 mutant-infected animals, wild-type-infected animals showed specific, 2-fold increases in CD8+ T cell concentrations in the white pulp/perirteriolar lymphoid sheaths and marginal zone (WP/PALS and MZ) at day 8 (Fig. 2D). By day 10, the CD8+ T cells had migrated to the red pulp (RP) (Fig. 2D and S2C and D). The 2-fold increase in specific
splenic zones detected by IHC analysis corresponded well to the 1.5-fold increase detected in the whole spleen by flow cytometry. IHC analysis showed no statistically significant differences in numbers of CD4^{+}/H11001 T cells or macrophages (Fig. S3). Although wild-type infections showed modest increases in CD8^{+}/H11001 and CD4^{+}/H11001 T cells in the liver (Fig. S4), the absolute number of CD8^{+} and CD4^{+} T cells in the spleen were 8- to 10-fold higher than in the liver (Table S3). Numbers of CD68^{+} cells were also increased in spleen (Table S3).

Together, these data revealed that in wild-type relative to Δmsp7 mutant infection, the major immune cell differences were in the spleen. Moreover, at day 10, the onset of parasite clearance, there was elevation in the number of CD8^{+} T cells in the spleen RP (where parasites are eliminated), suggesting that CD8^{+} T cells may be linked to blood-stage parasite clearance.

**Requirement of CD8^{+} T cells: effects on parasite control and anemia.** The requirement for CD8^{+} T cells in controlling blood-stage infection was tested in rats injected with anti-CD8α (Fig. 3A), which led to depletion of >95% of CD8^{+} T cells (Fig. 3B, left side). Levels of CD4^{+} T cells (Fig. 3B, right panel) and other immune cells (Fig. S5A and B) were unaffected. CD8^{+} T cell depletion had no significant effect on the rise in parasitemia or peak parasitemia. It blocked subsequent reduction of parasitemia (Fig. 3C), sustaining it through day 10 to 12, when parasites are usually eliminated. A time course of CD8^{+} T cell repletion suggests high-level restoration on day 15 and later (Fig. 3D). Immuni-
nohistochemical analysis at day 10 revealed that anti-CD8α resulted in a 2- to 3-fold reduction of splenic CD8+ T cells (Fig. 3E and F), with no effect on dendritic cells (see also Fig. S5C and D), and in an elevation of splenic parasites (Fig. 3G). Repletion in CD8+ T cells and the associated parasite clearance resulted in a deeper anemia (40% hemoglobin loss) (Fig. 3H).

Neither parasites alone (days 0 to 5) nor CD8+ T cells alone (days 18 to 22) induced anemia. Both were detected from days 6 to 16, and during the adaptive phase (days 10 to 14), parasite clearance mediated by CD8+ T cells was associated with severe anemia (40% hemoglobin loss) (Fig. 3H).

Activation of CD8+ T cells in the spleen is proportional to parasite load in the organ and soluble CD8 (sCD8) in plasma. Because CD8+ T cells regulate parasite clearance, day 10 is the onset of clearance, and the RP is a major site (15), we investigated the activation of CD8+ T cells at this time point in the spleen. Unfortunately, there are only a limited number of well-developed markers for cellular analysis in rats. As an alternative, we used microarray data that yielded extensive, genome-wide activation readouts and compared them to transcriptional signatures characteristic of murine CD8+ T cell activation elicited by viral and bacterial infections (16). These analyses revealed expression patterns typical of effector CD8+ T cells (downregulation of the interleukin 7 receptor [IL-7R] and Bcl-2 and upregulation of E2Fs) in splenocytes infected with the wild type and mutant compared to their uninfected counterparts (Fig. 4A; Table S2B). Further, among the differentially expressed genes in rats infected with the wild type versus the mutant, there are several (such as the granzyme genes) in common with those identified in murine effector CD8+ T cells (Fig. 4A).

Numbers of activated splenic CD8+ T cells were proportional to parasite load in the organ (Fig. 4B). We also examined sCD8,
because it is a form of the receptor released after activation (17, 18). sCD8 has been reported to be derived from CD4+ T cells in certain circumstances of viral infection, autoimmunity, and transplantation (19). However, in our model, the CD4+ T cell response is not altered between wild-type and msp7 mutant infections (Fig. S2) and CD4+ T cell numbers were not reduced when rats were perfused with anti-CD8α that immunodepleted CD8+ T cells (Fig. 3 and S5A), suggesting that the CD4+ CD8+ T cell subpopulation is not induced in malarial infection. Indeed, we find that plasma sCD8 levels strongly and positively correlated with CD8+ T cell number (Fig. 4C) (Spearman r = 0.9, P < 0.0001) and parasite load (Fig. 4D) (Spearman r = 0.8, P = 0.20).

Activated CD8+ T cells are known to directly kill intracellular pathogens (20–22). This requires antigen presentation by the major histocompatibility complex (MHC) class I, which we detected on both uninfected and infected reticulocytes as well as white cells (Fig. 4E). We further detected specific production of gamma interferon (IFN-γ) by CD8+ T cells stimulated with infected retic-
locytes in vitro (Fig. 4F), although the number of CD8+ T cells and infected cells were limiting because they were from the same animal (since this is an outbred model). Although we show that CD8+ T cells are (i) activated in response to blood-stage infection in vitro and (ii) control parasitemia in vivo, the lack of information on MHC class I presentation in this outbred rat model precludes establishing whether activation is indirectly or directly stimulated by infected erythrocytes.

Changes in properties of uninfected erythrocytes in malarial anemia. Under physiological conditions, the spleen is the major site of clearance of (aged and altered) erythrocytes. Since splenic clearance mechanisms detect changes in cellular properties of erythrocytes, we examined peripheral erythrocytes from infected rats on discontinuous Percoll gradients (Fig. 5A and B). On these gradients, infected erythrocytes (asterisk in Fig. 5A) and reticulocytes (Fig. 5A) were detected in the top light fraction (48%), while uninfected erythrocytes were detected at intermediate and higher densities (50% and greater). Visual representation and cell counts of various density fractions on different days suggested that infection increases the relative density of uninfected erythrocytes. As shown in Fig. 5B, at day 12 (a time of active erythrocyte removal), uninfected erythrocytes from all three infected animals consistently showed higher density fractions at 54%, 58%, and 60% Percoll, accounting for 20 to 40% of erythrocytes, which well corresponds to the extent of erythrocyte removal seen in this animal model. Since the spleen also has high concentrations of erythrocytes, we propose a splenic model for erythrocyte clearance associated with severe anemia (Fig. 5Ci and Cii). Here, parasite elimination results in the alteration of uninfected erythrocytes to limit their filtration through the spleen as well as to potentiate their removal by activated macrophages.

Elevation of the CD8+ T cell response associated with SMA in a case-control pediatric cohort infected with P. falciparum. Since the rat model is expected to better mimic the pathophysiology of human disease, the relevance of our findings to patient populations was investigated in a case-control pediatric cohort from Ibadan, Nigeria. The study design and details of clinical case definition are included in Materials and Methods. As shown in...
Fig. 6, plasma specimens from 268 children between the ages of 6 and 149 months (13 years) were analyzed. Two hundred eleven *P. falciparum*-infected children without neurological symptoms were separated on the basis of packed cell volume (PCV) into the SMA group (PCV, 5 to 15%; n = 48) and uncomplicated malaria (UM) group (PCV, 16 to 45%; n = 163). The UM group was further subdivided into groups with acute infection with no malarial anemia (AINMA) (PCV, 29 to 45%; n = 92) and mild malarial anemia (MMA) (PCV, 16 to 28%; n = 71). Also included were plasma samples from 57 age-matched community controls (CC) (PCV, 30 to 42%).

*P. falciparum* histidine-rich protein 2 (PfHRP2), the lead marker used to estimate total parasite mass (6, 7), was detected in over 89% of patient samples across disease groups (Fig. 6A). We found that higher plasma concentrations of PfHRP2 (and not peripheral parasitemia) were associated with SMA (Fig. 6B, section I). When the UM (AINMA and MMA) and SMA groups were combined, PCV levels inversely and significantly correlated with plasma levels of PfHRP2 (r = 0.43; P < 0.0001) or with estimated total parasite biomass (r = 0.42; P < 0.0001).

sCD8 was also significantly increased for SMA patients compared to levels in the CC (P = 0.004), AINMA (P = 0.09), or MMA (P = 0.021) group, although there was considerable variation in the data in all groups (Fig. 6B, section II). In humans, CD8+ T cell levels may reflect responses to liver infection (although this will not be reflected in the PfHRP2 biomass). Nevertheless, a univariate logistic regression analysis indicated that age (odds ratio [OR], 0.3-fold; 95% confidence intervals [CI95%], 0.2-to-0.6-fold) and weight (OR, 0.4-fold; CI95%, 0.2-to-0.7-fold) were significantly associated with a decreased risk of SMA in children (Table 1). However, this risk increased when the plasma concentrations of PfHRP2 (OR, 3.5-fold; CI95%, 1.7- to 7.1-fold) (but not peripheral parasitemia) or the estimated total parasite biomass (OR, 3.7-fold; CI95%, 1.8- to 7.5-fold) (but not the number of
circulating parasites) were elevated. The risk of SMA also increased when plasma sCD8 (OR, 2.4-fold; CI95%, 1.0- to 5.7-fold) was elevated (Table 1). Notably, the concomitant elevation in both plasma parameters was associated with a significant increased risk of SMA (OR, 7.2-fold; CI95%, 1.9- to 27.4-fold), suggesting that activated CD8^{+}/H11001 T cells and parasite biomass may act in conjunction, as predicted from the rat model. In infected children, this association was observed even after adjustment for age and weight (adjusted OR, 6.7-fold; CI95%, 1.7- to 25.7-fold) (Table 1).

**DISCUSSION**

Multiple host factors are known to influence malarial anemia (2, 23), but these are innate mechanisms (4, 24, 25). *P. berghei*-infected rats have historically been used to study anemia (26, 27). The rat spleen confers T cell immunity (28). CD4^{+}/H11001 T cells were proposed to eliminate anemia in a murine malaria model (8), but the study lacked quantitation of both CD4^{+} and CD8^{+} T cells. The same study also suggested that uninfected erythrocytes taken from anemic rats show normal clearance in uninfected rats, but we find that anemia is intrinsic to the infected spleen. Prior evidence indicates that CD8^{+} and/or CD4^{+} T cells may influence parasite biomass/infection in *P. berghei* and other malarias in rodents (29–33). Our data from the rat model show that the CD8^{+} T cells regulate parasite clearance and anemia as an adaptive (rather than an innate) immune response in the spleen. In future studies, spleenectomized rats may be used to further confirm the key role of the spleen, with the caveat that circulating parasitemias may be substantially higher.

With respect to mechanisms of anemia, our depletion experiments suggest that CD4^{+}-activated NK cells are not likely to be involved in parasite killing. Rather CD8^{+} T cell-induced parasite clearance may generate an intermediate(s) that stimulates innate clearance mechanisms of macrophages to trigger erythrocyte removal in the spleen (Fig. 5C). Moreover, infection changes properties of a large number of uninfected erythrocytes. This may further facilitate their uptake by activated macrophages as well as limit filtration through the splenic sinusoids, resulting in entrapment in the RP, and thus additionally potentiate clearance there (Fig. 5C). This may be due to steric or antigenic changes in uninfected erythrocytes that may be investigated in *in vitro* studies. Thus, although their exact nature has yet to be determined, changes in uninfected-erythrocyte properties may signify mechanisms of removal in the spleen analogous to those seen with inherited anemias (34).
Upon parasite clearance in humans, CD8+ T cell responses are clearly directly elicited by liver-stage infection (20, 21, 35, 36). Activation by blood-stage infection has also been suggested (36, 37). In our studies, the infections bypass the liver stage. Prior studies suggest that murine CD8+ T cells recognize blood-stage rodent malaria parasites (22, 38). Dendritic cells may contribute to the host response can in- 

- **TABLE 1 sCD8 is a risk factor for SMA and shows synergy with PHRP2 for development of a dual, preferred, predictive index of SMA**

| Characteristic          | OR     | CI<sub>95%</sub> (fold) | P value |
|-------------------------|--------|--------------------------|---------|
| Sex                     |        |                          |         |
| Male                    | 1      |                          |         |
| Female                  | 0.9    | 0.5–1.8                  | 0.79    |
| Age (yr)                |        |                          |         |
| Lower                   | 1      |                          |         |
| Higher                  | 0.3    | 0.2–0.6                  | 0.001   |
| Weight (kg)             |        |                          |         |
| Lower                   | 1      |                          |         |
| Higher                  | 0.4    | 0.2–0.7                  | 0.003   |
| Parasitemia (%)         |        |                          |         |
| Lower                   | 1      |                          |         |
| Higher                  | 1.4    | 0.7–2.8                  | 0.29    |
| Plasma PHRP2 (ng/ml)    |        |                          |         |
| Lower                   | 1      |                          |         |
| Higher                  | 3.5    | 1.7–7.1                  | 0.0005  |
| Plasma sCD8 (μg/ml)     |        |                          |         |
| Lower                   | 1      |                          |         |
| Higher                  | 2.4    | 1.0–5.7                  | 0.04    |
| Circulating parasite biomass |    |                          |         |
| Lower                   | 1      |                          |         |
| Higher                  | 0.8    | 0.4–1.6                  | 0.58    |
| Total parasite biomass  |        |                          |         |
| Lower                   | 1      |                          |         |
| Higher                  | 3.7    | 1.8–7.5                  | 0.0004  |
| Plasma samples with CD8-PHRP2 |    |                          |         |
| Lower-lower             | 1      |                          |         |
| Higher-lower            | 2.2    | 0.5–9.3                  | 0.30    |
| Lower-higher            | 2.8    | 0.6–12.1                 | 0.17    |
| Higher-higher           | 7.2    | 1/9/27.4                 | 0.004   |
| Multivariate logistic regression | |                          |         |
| Plasma samples with CD8-PHRP2 |    |                          |         |
| Lower-lower             | 1      |                          |         |
| Higher-lower            | 2.1    | 0.5–8.9                  | 0.33    |
| Lower-higher            | 2.6    | 0.6–11.4                 | 0.20    |
| Higher-higher           | 6.7    | 1/7/25.7                 | 0.006   |

*Univariate logistical-regression analysis was undertaken to determine the odds ratio (OR) associated with the risk of SMA for age, weight, PHRP2 level, estimated total parasite biomass, circulating parasites in the blood, and plasma sCD8. Adjusted values were used for age and weight.

**MATERIALS AND METHODS**

**Wisat rat model of *P. berghei* infection and anemia.** BALB/c mice were first injected intraperitonally (i.p.) with thawed stabiles of blood-stage *P. berghei* ANKA. Subsequently, live parasites isolated from mice were used to infect aged Wisat rats. Fifteen-week-old rats were injected i.p. with 105 wild-type or Δ*msp7* mutant parasites (10). Parasitemia, hemoglobin, and other blood parameters were monitored every 2 days. Parasite levels were monitored by performing Giemsa staining of thin blood film or qPCR, and hemoglobin (Hb) levels were determined by the method of Drabkins (as noted in reference 10).

**Microarray experiments and data analysis.** Spleens from 2 wild-type-parasite-infected, 2 Δ*msp7* mutant-infected, and 2 uninfected rats (15 weeks of age) were surgically harvested, kept in RNAlater, and stored at −20°C until used. RNA was isolated using a Roche MagNA Pure compact automated system, and labeling was done using a MessageAmp Premier RNA amplification kit (Invitrogen). Affymetrix rat 430 2.0 array hybridizations were performed by the UCLA Clinical Microarray Core, UCLA, Los Angeles, CA, according to the standard Affymetrix GeneChip expression analysis protocol. RNA from each animal was profiled individually. Thresholds for selecting significant genes were set at a relative difference of ≥1.5-fold, an absolute difference of ≥100 signal intensity units, and a P of <0.05. Genes that met all three criteria were considered significantly changed.

**General histopathology and analysis.** Spleen, liver, lung, brain, and kidney were harvested from rats not infected or infected with wild-type or Δ*msp7* parasites. Harvested organs were cut into smaller portions and placed into fixative (10% neutral buffered formalin) for at least 48 h at room temperature. Samples were then processed and paraffin embedded at AML Laboratories Inc. (Baltimore, MD), and thin sections (3 to 4 μm) were produced with a microtome and stained with hematoxylin and eosin (H&E).

**Immunohistochemistry and imaging.** Mouse monoclonal antibodies (Mabs) utilized were anti-rat (i) CD8α (clone OX-8, catalog no. MCA48G), (ii) CD4 (clone W3/25, no. MCA55R), (iii) CD68 (clone ED1, no. MCA341R); AbD Serotec, Oxford, United Kingdom), and (iv) OX 62 for dendritic cells (DC) (clone OX-62, no. MCA1029GA; AbD Serotec, Oxford, United Kingdom; also referred to as anti-DC). Formalin paraffin-embedded spleen or liver sections (3 to 4 μm) were dewaxed in xylene. For samples probed by Mabs anti-CD4, anti-CD68, and anti-DC, antigen retrieval required preincubation of deparaffinized samples with 0.05% proteinase K (Dako, Hamburg, Germany; no. S3004) in 0.05 mol/liter Tris-HCl (pH 7.5) for 8 min at room temperature (RT). After being washed, sections were immersed in 3% H2O2 in phosphate-buffered saline (PBS) for 20 min at RT to block endogenous peroxidase. After an additional wash, the sections were treated with 5% horse serum for 30 min, followed by successive incubation in avidin and biotin (no. SP-2001 avidin/biotin blocking kit; Vector Laboratories) to block endogenous biotin. Anti-CD8α (dilution, 1/100), anti-CD4 (dilution, 1/100), anti-CD68 (dilution, 1/500), or anti-DC (dilution, 1/100) was applied to the sections in PBS with 1% horse serum and kept overnight at 4°C (for Mabs anti-CD8α, anti-CD4, and anti-DC) or for 60 min at RT (for Mab anti-CD68). Affinity-purified, biotinylated, and rat absorbed horse anti- 

- **mbio.asm.org 9**

January/February 2015 Volume 6 Issue 1 e02493-14
with Mayer’s hemalum. The slides were then mounted in Cytoseal XYL (no. 8312-4; Thermo Scientific, Kalamazoo, MI, USA). Incubations for negative controls were carried out with sections incubated with normal mouse IgG1 (no. MCA1209; AbD Serotec, Oxford, United Kingdom) or in the absence of the primary antibody.

For each spleen slide, images were collected within the follicle (white pulp [WP]) and the adjacent marginal zone (MZ; marginal sinus included) and red pulp (RP). Follicles with a clear differentiation between the white pulp, the adjacent MZ, and the RP were selected for imaging. The collection of the images was done at a magnification of ×1,000 (high-power fields [HPF]). The images of all areas of the follicle and the adjacent MZ were collected, while at least 10 randomly selected fields in the adjacent RP around the follicle were collected. Pictures were acquired on a Nikon Olympus microscope using a Nikon digital DS-Fi1-U2 camera controlled by NIS-Elements F3.0 Nikon software (all from Nikon Instruments Inc., Tokyo, Japan). Images were visualized with a DPlan Apo 40×/0.10 oil immersion or an DPlan Apo 100×/1.30 oil immersion objective lens (Nikon). For each sample, positive cells were counted and localized on at least two follicles with the adjacent MZ and RP.

For each liver slide, images were collected within the entire tissue sample at a magnification of ×1,000. For each type of cellular stain (CD8+ T cells, CD4+ T cells, CD68+ cells, or DC), more than 600 photographs were analyzed. The densities of CD8+ T cells, CD4+ T cells, CD68+ cells, or DC were estimated as the number of positive cells per HPF.

**Live-cell immunofluorescence assay.** Fluorescein isothiocyanate (FITC) mouse monoclonal anti-RT1A (clone OX-18, catalog no. 554919; BD Biosciences, USA) was used to detect MHC class I. Phycerythrin (PE) mouse anti-rat CD71 (clone OX-26, no. 554891) was used to detect rat CD71. Fresh blood was collected, washed with PBS (pH = 7.4), and then incubated with anti-RT1A and anti-CD71 (4 μg/ml) diluted in PBS-bovine serum albumin (BSA; 2%) for 30 min on ice under slight agitation. After five washes with PBS, cell nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI) for 5 min. Cells were then washed with PBS and fixed with PBS-formaldehyde (1%). Slides were mounted with Vectashield medium (Vector Laboratories, Burlingame, CA) for imaging. Images were visualized with a 100x oil immersion objective lens and captured using an inverted Olympus IX fluorescence microscope and a CoolSnap HQ2 charge-coupled-device (CH550/LCCD) camera controlled by DeltaVision software (Applied Precision, Seattle, WA).

**Percoll density gradients.** Discontinuous Percoll density gradients (Sigma-Aldrich, St. Louis, MO, USA) consisting of 1.5-ml fractions, with densities ranging from 48 to 64% Percoll in RPMI medium, were assembled as indicated in Fig 5A. Peripheral blood was collected from uninfected and infected animals, washed three times, and diluted in RPMI medium (hemocrit = 80%). From this suspension, 1 ml was layered on the Percoll gradient and separated by centrifugation at 3,000 rpm for 40 min at 19°C. Fractions were collected by careful pipetting. The number of cells per fraction was counted using a Malassez chamber.

**RNA extraction.** For each spleen sample, three sections (5 μm each) separated by 50 μm were collected and pooled for RNA extraction. Total RNA was extracted with an RNeasy FFPE kit (reference no. 73500; Qiagen) according to the manufacturer’s instructions. RNA extracts were quantified using a NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, DE, USA). The integrity of the RNA was controlled with an RNA nano chip (2100 Bioanalyzer; Agilent Biotechnologies, Wilmington, DE). Samples were immediately stored at −20°C.

**Quantitative real-time PCR.** Primers were designed from the P. berghei Anka 18S rRNA gene (GenBank accession no. AJ435131.1) and the rat GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene (GenBank accession no. NM_017008). The sequence of the specific primers for P. berghei 18S RNA and rat GAPDH were 18S RNA forward (5’ AATCT TGAACGAGGAAATGCTTACGTG 3’), 18S RNA reverse (5’ AGCCGGCTGTGTCACAAGG 3’), GAPDH forward (5’ TGGCCCTCAAGGAGTAAAGAAC 3’), and GAPDH reverse (5’ GGCGGCTCTCTTGCCCTCAGTATC 3’). Amplification of the GAPDH sequence followed the internal control for normalization. qPCR was performed using the 7900 HT Fast real-time PCR system (Applied Biosystems) with a 20-μl reaction volume and the Power SYBR Green RNA-to-CT one-step kit (catalog reference no. 4389986; Applied Biosystems). Serial dilutions of the cDNA (1:1, 1:10, 1:100, 1:1,000, 1:10,000) with nuclease-free water (reference no. AM9935; Applied Biosystems) were used to generate a relative standard curve for 18S RNA as well as GAPDH. The concentrations of target sequence in the samples are extrapolated from the standard curve. The quantities were normalized by dividing the quantity of the 18S RNA by the quantity of the GAPDH.

**Spleen lymphocyte isolation and characterization by flow cytometry.** To isolate lymphocytes, spleens were harvested from rats infected with wild-type and Δmsp7 mutant parasites on day 8 and day 10. Total spleenocytes were isolated, erythrocytes were lysed, and residual cells were stained for B (CD45RA), NK (CD161a), and CD3 (CD4 and CD8) cells. Subsets of cells were identified by first gating them on lymphocytes by forward and side scatter. CD3 singly positive cells were then analyzed for CD4 and CD8 expression. A suitable isotype control for each antibody was included as a control, and compensation was performed wherever required. Events were recorded in a Beckman Coulter FC500 flow cytometer and data analyzed with FlowJo.

**In vitro stimulation of CD8+ T cells with wild-type parasites.** Whole blood was separated in two parts, one for peripheral blood mononucleated cells (PBMCs) and CD8+ T cell purification and the other part for infected-erythrocyte purification. Erythrocytes were lysed with NH4Cl, and the cells were washed twice in fresh medium. CD8+ T cells were purified with positive selection using a magnetically activated cell sorting (MACS) cell separation system (Miltenyi Biotech, USA) according to the manufacturer’s protocols. The purity of CD8+ T cells was 95%. Infected erythrocytes were obtained as described previously (43).

For the in vitro stimulation assay, 105 purified CD8+ T cells were stimulated with 105 purified infected erythrocytes (with ~40% infected reticulocytes) suspended in 200 μl incubation medium (RPMI 1640 plus 1-glutamine plus neomycin plus 30% fetal bovine serum) for 72 to 82 h, and the levels of IFN-γ in the supernatant were determined by a sandwich enzyme-linked immunosorbent assay (ELISA). Uninfected erythrocytes and staphylococcal enterotoxin B antigen (SEB; 5 μg/ml; Sigma) were used as negative and positive controls, respectively.

**Animal procedures.** Animal protocols were reviewed and approved by the institutional animal care and use committees of Northwestern University (protocol no. 2006-0935) and the University of Notre Dame (protocol no. 11-070).

**Ethics statement.** Parents or guardians of study participants gave informed written consent. The research was approved by the internationally accredited joint ethics committees of the College of Medicine of the University of Ibadan and the University College Hospital, Ibadan, Nigeria. All procedures with human subjects were approved by the Institutional Review Board of the University of Notre Dame.

**Patient study design and sample collection.** All study participants of this case-control study were recruited during 2009 to 2012. Children with malaria were recruited by the Childhood Malaria Research Group (CMRG) at the University College Hospital (UCH), Ibadan, Nigeria. Community control (CC) children (malaria negative) were recruited from local vaccination clinics and school visits from multiple districts of Ibadan.

The children were from 6 months to 13 years old. They were screened for parasite detection by microscopy following Giemsa staining of thick and thin blood films as performed routinely at the UCH. Clinical definitions used were as indicated by the WHO criteria for severe P. falciparum malaria (44). All infected children were positive for P. falciparum. Uncomplicated malaria (UM) cases were additionally defined as febrile with a PCV (packed cell volume) of >20% (not requiring hospital admission). Severe malarial anemia (SMA) cases showed PCVs of <16%. CC children appeared healthy, without any disease symptoms. They were P. falciparum negative in both thick and thin Giemsa smears and selected for age and sex
match with the patient group. The clinical data were compiled for each patient; blood samples were collected in an EDTA tube, and the plasma was separated (1,000 × g, 10 min), aliquoted, and frozen at −80°C until used.

Quantitative analyses of P falciparum, parasite biomass, the sequestration index, and sCD8. The quantification of P. falciparum histidine-rich protein 2 (PfHRP2) in the plasma of malaria patients was carried out by sandwich ELISA essentially as previously described (6). Briefly, the mouse monoclonal Ab anti-P. falciparum HRP2 IgM (MPFM-55A; Immunology Consultants Laboratory Inc., USA) and horseradish peroxidase (HRP)-conjugated anti-P. falciparum IgG (MPFG-55P; Immunology Consultants Laboratory Inc., USA) were used for plate coating and for detection, respectively. The detection limit of the assay was 31.25 pg/ml. Positive cases were defined as those in which duplicate derived concentrations were greater than the detection limit. Each ELISA plate contained samples from UM patients and from age-matched SMA patients.

Circulating and whole-body parasite biomasses were calculated using the previously reported formulas (6, 7). Total parasite biomass was calculated only from individuals with detectable PfHRP2 in the plasma. The sequestration index was calculated as the total parasite burden divided by the circulating burden (45).

Plasma sCD8 ELISA. Plasma quantification of sCD8 was done by a sandwich ELISA using the mouse monoclonal antibody anti-human CD8α (clone D-9, sc-7970; Santa Cruz Biotechnology, Inc.), which recognizes both human and rat sCD8, as the primary antibody and the rabbit polyclonal antibody anti-human CD8α (clone H–160, sc-7188; Santa Cruz Biotechnology, Inc.) as the secondary antibody; these were detected by the HRP-conjugated goat polyclonal Ab anti-rabbit IgG (H+L) (PI-1000; Vector Laboratories). Each ELISA plate contained samples from CC patients and from age-matched UM and SMA patients.

Statistical analysis. The Wilcoxon signed-rank test for matched pairs was used to compare continuous outcomes at different time points. The Mann-Whitney U test, Student’s t test, Kruskal-Wallis test, or one-way analysis of variance (ANOVA) with a Tukey or Bonferroni post hoc analysis was used to compare continuous outcomes of different groups at the same time point. The correlation between different continuous measures was determined using the Spearman correlation coefficient.

SMI risk factors were evaluated using univariate and multivariate logistic-regression models. The binary outcome (yes/no) was a dependent variable. Eight independent variables were studied: sex, age, body weight, peripheral parasitemia, plasma concentrations of PfHRP2 and sCD8, and the estimated circulating and total parasite biomasses. Apart from sex, all independent variables were coded as binary (high or low according to the median). Since in the rat model we show that concomitant increases of parasite clearance and CD8 T-cell number predict anemia, we defined another independent variable, which is the combination of plasma concentrations of PfHRP2 and sCD8. This last variable has 4 classes according to the median (low and high for plasma concentrations of both sCD8 and PfHRP2, low plasma concentrations of sCD8 and high concentrations of PfHRP2, and high plasma concentrations of sCD8 and low concentrations of PfHRP2). The effects of independent variables for the risk of developing SMA were evaluated using unconditional univariate regression analysis. The factors significant at a level of 0.05 in the univariate analysis were then included in a multivariate logistic model. All statistical analyses were performed with SPSS statistical software (PASS statistical version 18). All P values were two sided, and those <0.05 were considered significant.

SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.02493-14/-/DCSupplemental.

Figure S1, PDF file, 0.3 MB.
Figure S2, GIF file, 0.5 MB.
Figure S3, GIF file, 0.9 MB.
Figure S4, PDF file, 0.5 MB.
Figure S5, PDF file, 0.2 MB.
Figure S6, PDF file, 0.02 MB.

Table S1, PDF file, 0.01 MB.
Table S2A, PDF file, 0.1 MB.
Table S2B, XLS file, 0.03 MB.
Table S3, PDF file, 0.03 MB.

ACKNOWLEDGMENTS
We thank Souvik Bhattacharjee for recombinant HRP2 and Trupti Pandharipande for comparative analysis of rat and murine genes and bioinformatic analyses.

This work was supported by the NIH (grants P01 HL078826 to K.H., A.H., N.M., P.B., and R.T.; R01HL069630 and R01AI039071 to K.H.; and F31 HL09277 to N.D.G.) and the UK Medical Research Council (grants U117532067 to A.H. and D.F.-R. and G0900109 to R.T.). The authors declare no competing financial interests.

Innocent Safeukui, Rama Akondy, David Olaleye, Rafi Ahmed, Anthony Holder, Olugbemiro Sodeinde, James Kazura, Narla Mohandas, Delmiro Fernandez-Reyes, and Kasturi Haldar designed the research; Innocent Safeukui, Noé D. Gomez, Aanuoluwa A. Adelani, Florence Burte, Nathaniel K. Afolabi, Rita Tewari, and Biobele J. Brown performed the research; Innocent Safeukui, Noé D. Gomez, Aanuoluwa A. Adelani, Florence Burte, Nathaniel K. Afolabi, Rita Tewari, Rafi Ahmed, Anthony Holder, Rita Tewari, Pierre Buffet, Biobele J. Brown, Wuraola A. Shokunbi, David Olaleye, Olugbemiro Sodeinde, James Kazura, Rafi Ahmed, Narla Mohandas, Delmiro Fernandez-Reyes, and Kasturi Haldar analyzed the data and interpreted the results; Nathaniel K. Afolabi, Biobele J. Brown, Wuraola A. Shokunbi, David Olaleye, Olugbemiro Sodeinde, James Kazura, Rafi Ahmed, Narla Mohandas, Delmiro Fernandez-Reyes, and Kasturi Haldar wrote the paper; and Peter Velazquez, designed the research, analyzed the data, and interpreted the results.

REFERENCES
1. WHO. 2012. Malaria report 2012. WHO, Geneva, Switzerland. http://www.who.int/malaria/publications/world_malaria_report_2012/wmr2012_summary_en.pdf.
2. Miller LH, Baruch DI, Marsh K, Doumbo OK. 2002. The pathogenic basis of malaria. Nature 415:673–679. http://dx.doi.org/10.1038/415673a.
3. Menendez C, Fleming AF, Alonso PL. 2000. Malaria-related anaemia. Parasitol Today 16:469–476. http://dx.doi.org/10.1016/S0169-4758(00)01774-9.
4. Buffet PA, Safeukui I, Deplaine G, Brousse V, Prendki V, Thellier M, Turner GD, Mercereau-Pujol O. 2011. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 117:381–392. http://dx.doi.org/10.1182/blood-2010-04-202911.
5. Hedberg K, Shaffer N, Davachi F, Hightower A, Hyman CJ, Paluku KM, Nguyen-Dinh P, Bremans JG. 1993. Plasmodium falciparum-associated anaemia in children at a large urban hospital in Zaire. Am J Trop Med Hyg 48:365–371. http://www.ajtmh.org/content/48/3/365.long.
6. Dondorp AM, Desakorn V, Longtanrompinyo W, Sahassananda D, Silamut K, Chotivanich K, Newton PN, Pitsutthitum P, Smithyman AM, White NJ, Day NP. 2005. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med 2:e204. http://dx.doi.org/10.1371/journal.pmed.0020204.
7. Hendriksen IC, Mwanga-Amumaire P, van Seidelein L, Mtove G, White L, Olaosebikan R, Lee SJ, Tshefu AK, Woodrow C, Ams B, Karema C, Siawae S, Maitland K, Gomes E, Pan-Ngum W, Gesase S, Silamut K, Reyburn H, Joseph S, Chotivanich K, Fanello CI, Day NP, White NJ, Dondorp AM. 2012. Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement. PLoS Med 9:e1001297. http://dx.doi.org/10.1371/journal.pmed.1001297.
8. Evans KJ, Hansen DS, van Roorien J, Buckingham LA, Schofield L. 2006. Severe malarial anaemia of low parasite burden in rodent models results from accelerated clearance of uninfected erythrocytes. Blood 107:1192–1199. http://dx.doi.org/10.1182/blood-2005-08-3460.
9. Lamikanra AA, Brown D, Potocnik A, Casals-Pascual C, Langhorne J, Roberts JD. 2007. Malarial anemia: of mice and men. Blood 110:18–28. http://dx.doi.org/10.1182/blood-2006-09-018069.

10. Gómez ND, Safeukui I, Adelani AA, Tewari R, Reddy JK, Rao S, Holder A, Buffett P, Mohandas N, Haldar K. 2011. Deletion of a malaria invasion gene reduces death and anemia, in model hosts. PLoS One 6:e25477. http://dx.doi.org/10.1371/journal.pone.0025477.

11. Thawani N, Tam M, Bellemare MJ, Bohle DS, Olivier M, de Souza JB, Stevenson MM. 2014. Plasmodium products contribute to severe malarial anemia by inhibiting erythropoietin-induced proliferation of erythroid precursors. J Infect Dis 209:140–149. http://dx.doi.org/10.1093/infdis/jit147.

12. Millot S, Andrieu V, Letteron P, Lysoumi S, Hurtado-Nedelec M, Karim Z, Thibodeau D, Bennis B, Charrier JL, Lasocki S, Beaumont C. 2010. Erythropoietin stimulates spleen BMP4-dependent stress erythropoiesis and partially corrects anemia in a mouse model of generalized inflammation. Blood 116:6072–6081. http://dx.doi.org/10.1182/blood-2010-04-281840.

13. Chen LT. 1980. Intrasplenic microcirculation in rats with acute hemolytic anemia. Blood 56:737–740. http://www.bloodjournal.org/content/56/4/737.long.

14. Deplaine G, Safeukui I, Jeddi F, Lacoste F, Brousse V, Perrot S, Biligui S, Guillote M, Guitton C, Dokmak S, Aussilhou B, Sauvanet A, Casals Hatem D, Paye F, Thellier M, Mazier D, Milan G, Mohandas N, Mercereau-Puijalon O, David PH, Buffet PA. 2011. The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood 117:889–895. http://dx.doi.org/10.1182/blood-2010-11-32801.

15. Safeukui I, Correas JM, Brousse V, Hirt D, Deplaine G, Mule S, Lesurlet M, Goasguen N, Sauvanet A, Couvelard A, Kerenji S, Khun H, Vigan-Molin G, Ottoline MJ, Tréjolier Y, Mercereau-Puijalon O, Milan G, David PH, Buffet PA. 2008. Retention of Plasmodium falciparum ring-infected erythrocytes in the slow, open microcirculation of the human spleen. Blood 112:2520–2528. http://dx.doi.org/10.1182/blood-2008-03-146779.

16. Deplaine G, Blair DA, Knell J, Yang E, Mayva Y, Doedens A, Dustin ML, Goldarath AW, The Immunological Genome Project Consortium. 2013. Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation. Nat Immunol 14:404–412. http://dx.doi.org/10.1038/ni.2536.

17. Fujimoto J, Levy S, Levy R. 1983. Spontaneous release of the lu-2 (T) molecule from human T cells. J Exp Med 158:752–766. http://jem.rupress.org/content/158/3/752.long. http://dx.doi.org/10.1083/jem.158.3.752.

18. Tomkinson BE, Brown MC, Ip SH, Carrabis S, Sullivan JL. 1989. Soluble CD8 during T cell activation. J Immunol 142:2230–2236. http://dx.doi.org/10.4049/jimmunol.142.4.2230.

19. Kenny E, Mason D, Saoudi A, Pombo A, Ramirez F. 2004. CD8 alpha is an activation marker for a subset of peripheral CD4+ T cells. Eur J Immunol 34:1262–1271. http://dx.doi.org/10.1002/eji.200324363.

20. Overstreet MG, Cockburn IA, Chen YC, Zavala F. 2008. Protective CD8 T cells against plasmodium liver stages: immunobiology of an "unnatural" immune response. Immunity 22:272–283. http://dx.doi.org/10.10111/j.1600-065X.2008.00671.x.

21. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurenbs MB, Gunasekara A, Chakravarty S, James ER, Seadegh M, Richman A, Velmuragan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stahlman MT, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Kominar J, Thomas N, Lovenyes M, Birkett A, Powell CV, Loucq C, Edelman R, Richtie TL, Hoffman SL. 2011. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cells and IFN-y mediate the time-dependent accumulation of infected red blood cells in deep organs during experimental cerebral malaria. PLoS One 6:e25477. http://dx.doi.org/10.1371/journal.pone.0025477.

22. Horne-Debets JM, Faleiro R, Karunaratne DS, Liu XQ, Liborg KE, Poh CM, Grottenberg GM, Hill GR, MacDonald KP, Good MF, Renia L, Ahmed R, Sharpe AH, Wykes MN. 2013. PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. Cell Rep 5:1204–1213. http://dx.doi.org/10.1016/j.celrep.2013.11.002.

23. Embury SH, Clark MR, Monroy G, Mohandas N. 1984. Concurrent sickle cell anemia and alpha-thalassemia. Effect on pathological properties of sickle erythrocytes. J Clin Invest 73:116–123. http://dx.doi.org/10.1172/JCI11181.

24. Seidough A, Sim BK, Mason C, Nutman T, Malik A, Roberts C, Johnossa I, Ochola J, Kech D, Were B, Hoffman SL. 1992. Naturally acquired CD8+ cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. J Immunol 149:966–971. http://dx.doi.org/10.4049/jimmunol.149.3.966.long.

25. Good MF, Doolan DL. 2010. Malaria vaccine design: immunological considerations. Immunity 33:555–566. http://dx.doi.org/10.1016/j.immuni.2010.10.003.

26. Pombo DJ, Lawrence G, Hirunpetchchat C, Rczpczczyk C, Bryden M, Cloanon N, Anderson K, Mahakunkijcharoen Y, Martin LB, Wilson D, Elliott S, Elliott S, Eison DP, Weinberg JB, Saul A, Good MF. 2002. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360:610–617. http://dx.doi.org/10.1016/S0140-6736(02)09784-2.

27. Howland SW, Poh CM, Gun SY, Class C, Mullerer B, Guo SY, Zavala F. 2015. Protective CD8+ T cell responses to Plasmodium falciparum and Plasmodium vivax liver stages. Cell Rep 20:272–283. http://dx.doi.org/10.10111/j.1600-065X.2008.00671.x.

28. Imair T, Ishida H, Suseki K, Hiirai M, Tamuguchi T, Okada H, Suzuki T, Shimokawa C, Hisaeda H. 2013. CD8+ T cell activation by murine erythroblasts infected with malaria parasites. Sci Rep 3:1572. http://dx.doi.org/10.1038/srep01572.

29. Perkins DJ, Were T, Davenport GC, Kempaiah P, Hittner JB, Ong'echa JM. 2011. Severe malarial anemia: innate immunity and pathogenesis. Int J Biol Sci 7:1427–1442. http://dx.doi.org/10.7150/ijbs.7.1427.

30. Wartumnb JM, Opollo MO, Muga RO, Mioso AO, Stoute J. 2008. Red cell surface changes and erythrophagocytosis in children with severe Plasmodium falciparum anemia. Blood 95:1481–1486. http://www.bloodjournal.org/content/bloodjournal/95/4/1481.full.pdf.

31. Shimokawa C, Fried M, Domingo D, Kohl P. 2012. CD8+ T cells and IFN-y mediate the time-dependent accumulation of infected red blood cells in deep organs during experimental cerebral malaria. PLoS One 6:e25477. http://dx.doi.org/10.1371/journal.pone.0025477.

32. Jones TR, Storckwick DF, Gozio AL, Obaldia N, III, Andersen EM, Lucas C, Narum DL, Magill AJ, Sim BK, Hoffman SL. 2002. Anemia in parasite- and recombinant protein-immunized aotus monkeys infected with Plasmodium falciparum. Am J Trop Med Hyg 66:672–679. http://dx.doi.org/10.4269/ajtmh.2002.66.6.672.long.
41. Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, Sissoko MS, Kone M, Diallo AI, Saye R, Guindo MA, Kante O, Niambele MB, Miura K, Mullen GE, Pierce M, Martin LB, Dolo A, Diallo DA, Doumbo OK, Miller LH, Saul A. 2009. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27:3090–3098. http://dx.doi.org/10.1016/j.vaccine.2009.03.014.

42. Ellis RD, Fay MP, Sagara I, Dicko A, Miura K, Guindo MA, Guindo A, Sissoko MS, Doumbo OK, Diallo D. 2011. Anaemia in a phase 2 study of a blood stage falciparum malaria vaccine. Malar J 10:13. http://dx.doi.org/10.1186/1475-2875-10-13.

43. Janse CJ, Ramesar J, Waters AP. 2006. High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite Plasmodium berghei. Nat Protoc 1:346–356. http://dx.doi.org/10.1038/nprot.2006.53.

44. World Health Organization. 2000. Severe falciparum malaria. World Health Organization, communicable diseases cluster. Trans R Soc Trop Med Hyg 94(Suppl 1):S1–S90. http://whqlibdoc.who.int/publications/2000/TropMedandHygiene_2000_94_S1_pp1-10.pdf.

45. Silamut K, Phu NH, Whitty C, Turner GD, Louwrier K, Mai NT, Simpson JA, Hien TT, White NJ. 1999. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol 155:395–410. http://dx.doi.org/10.1016/S0002-9440(10)65136-X.